Selected article for: "active replication and viral replication"
Author: Roman Woelfel; Victor Max Corman; Wolfgang Guggemos; Michael Seilmaier; Sabine Zange; Marcel A Mueller; Daniela Niemeyer; Patrick Vollmar; Camilla Rothe; Michael Hoelscher; Tobias Bleicker; Sebastian Bruenink; Julia Schneider; Rosina Ehmann; Katrin Zwirglmaier; Christian Drosten; Clemens Wendtner
Title: Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster
  • Document date: 2020_3_8
    • ID: gunn55f9_1
    Snippet: Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 X 10 8 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat-and lung-derived samples, but not from stool samples in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populati.....
    Document: Pharyngeal virus shedding was very high during the first week of symptoms (peak at 7.11 X 10 8 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat-and lung-derived samples, but not from stool samples in spite of high virus RNA concentration. Blood and urine never yielded virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. Sequence-distinct virus populations were consistently detected in throat-and lung samples of one same patient. Shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 6-12 days, but was not followed by a rapid decline of viral loads. COVID-19 can present as a mild upper respiratory tract illness.

    Search related documents:
    Co phrase search for related documents
    • active replication and high virus RNA concentration: 1
    • active replication and high virus RNA concentration spite: 1
    • active replication and infectious virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active replication and lung throat: 1
    • active replication and mild upper respiratory tract illness: 1
    • active replication and mild upper respiratory tract illness present: 1
    • active replication and pharyngeal virus: 1
    • active replication and pharyngeal virus shedding: 1
    • active replication and rapid decline: 1
    • active replication and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • high virus and infectious virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high virus and lung throat: 1
    • high virus and mild upper respiratory tract illness: 1
    • high virus and mild upper respiratory tract illness present: 1
    • high virus and pharyngeal virus: 1, 2, 3
    • high virus and pharyngeal virus shedding: 1
    • high virus and rapid decline: 1
    • high virus and respiratory tract: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • high virus RNA concentration and respiratory tract: 1